Asset
Zunsemetinib
Aclaris Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05279417 | phase2 | completed | 2022-02-01 | 2023-09-05 | Aclaris Therapeutics, Inc. | ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA) |
| NCT05216224 | phase2 | completed | 2021-12-29 | 2022-12-23 | Aclaris Therapeutics, Inc. | ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) |
| NCT04247815 | phase2 | completed | 2020-03-16 | 2021-02-04 | Aclaris Therapeutics, Inc. | Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA |
| NCT04524858 | phase2 | terminated | 2020-10-23 | 2021-02-25 | Aclaris Therapeutics, Inc. | Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) |
| NCT05511519 | phase2 | terminated | 2022-07-12 | 2023-12-06 | Aclaris Therapeutics, Inc. | Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis |
FDA applications (0)
This company has no applications containing this asset.